指南与共识炎症性肠病

炎症性肠病生物制剂治疗药物监测的文献综述与专家共识

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
指南 / 共识 · Am J Gastroenterol · 2021-01-01

该共识采用改良德尔菲法,经文献综述形成45条陈述,由10名IBD与TDM专家匿名评分,最终48/49条达成共识。共识推荐对全部生物制剂进行反应性TDM,抗TNF治疗可 proactive TDM,英夫利西单抗或阿达木单抗浓度未达至少10-15 μg/mL前不应停药。

要点

  • 反应性TDM适用于所有生物制剂的原发无应答和继发失应答。
  • 英夫利西单抗或阿达木单抗浓度未达至少10-15 μg/mL前不应考虑停药。
  • 抗TNF治疗推荐诱导后及维持期至少一次进行proactive TDM。

核心结论

  • 多数情况下TDM在IBD中的效用达成共识,尤其是抗TNF的反应性与proactive TDM。

研究设计与样本

  • 采用改良德尔菲法,经文献综述形成45条陈述,由10名IBD与TDM专家匿名评分(1-10分)。

主要发现

  • 虚拟会议中8条陈述改写、7条新提、19条重新评分,最终48/49条达成共识。

关键数值与推荐

  • 陈述评分≥7且80%以上参与者同意即被接受。
  • 反应性TDM应用于所有生物制剂的原发无应答和继发失应答。
  • 英夫利西单抗或阿达木单抗浓度至少达10-15 μg/mL前不应考虑停药。
  • 抗TNF治疗推荐诱导后及维持期至少一次进行proactive TDM。

临床怎么用

  • 对生物制剂原发无应答或继发失应答者应行反应性TDM。
  • 英夫利西单抗或阿达木单抗治疗中,浓度未达至少10-15 μg/mL前不宜停药。
  • 抗TNF治疗诱导后及维持期至少一次proactive TDM。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to provide a consensus statement regarding the clinical utility of TDM for biologics in inflammatory bowel disease (IBD). A modified Delphi method was applied to develop consensus statements. A comprehensive literature review was performed regarding TDM of biologic therapies in IBD, and 45 statements were subsequently formulated on the potential application of TDM in IBD. The statements, along with literature, were then presented to a panel of 10 gastroenterologists with expertise in IBD and TDM who anonymously rated them on a scale of 1-10 (1 = strongly disagree and 10 = strongly agree). An expert consensus development meeting was held virtually to review, discuss, refine, and reformulate statements that did not meet criteria for agreement or that were ambiguous. During the meeting, additional statements were proposed. Panelists then confidentially revoted, and statements rated ≥7 by 80% or more of the participants were accepted. During the virtual meeting, 8 statements were reworded, 7 new statements were proposed, and 19 statements were rerated. Consensus was finally reached in 48/49 statements. The panel agreed that reactive TDM should be used for all biologics for both primary nonresponse and secondary loss of response. It was recommended that treatment discontinuation should not be considered for infliximab or adalimumab until a drug concentration of at least 10-15 μg/mL was achieved. Consensus was also achieved regarding the utility of proactive TDM for anti-tumor necrosis factor therapy. It was recommended to perform proactive TDM after induction and at least once during maintenance. Consensus was achieved in most cases regarding the utility of TDM of biologics in IBD, specifically for reactive and proactive TDM of anti-tumor necrosis factors.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Cheifetz AS, Abreu MT, Afif W, et al. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol. 2021. PMID: 34388143. doi:10.14309/ajg.0000000000001396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。